Scholarlink

Introduction <p>Distinguishing active inflammatory or remodeling-associated processes from irreversible fibrosis in systemic sclerosis remains challenging using conventional imaging modalities. The tracer [<sup>68</sup>Ga]Pentixafor targets the C-X-C motif chemokine receptor 4 (CXCR4) which is expressed on leukocytes. Uptake of [<sup>68</sup>Ga]Pentixafor may provide complementary biological information on CXCR4-associated inflammatory and remodeling activity.</p> Methods <p>This prospective cohort study included patients with early SSc (disease duration ≤ 5&#xa0;years) and preexisting interstitial lung disease. All patients underwent [<sup>68</sup>Ga]Pentixafor-PET/CT imaging. Normalized [<sup>68</sup>Ga]Pentixafor uptake was quantified using the target-to-background ratio (TBR). Follow-up data on disease progression was collected. A control group comprised patients with giant cell arteritis.</p> Results <p>Twelve patients with SSc were included. The highest [<sup>68</sup>Ga]Pentixafor uptake was observed in the hilar and mediastinal lymph nodes, in fibrotic lung regions, and in the left ventricular myocardium. In all three regions, a significantly higher [<sup>68</sup>Ga]Pentixafor uptake was measured in SSc compared to controls (median TBR of lymph nodes 3.5 [IQR 2.7 – 4.3] vs 1.6 [1.3 – 2.0] <i>p</i> &lt; 0.0001; inferior lung lobes 2.3 [1.6 – 2.8] vs 0.8 [0.7 – 1.0], <i>p</i> &lt; 0.0001; and left ventricle 2.0 [1.4 – 2.4] vs 1.3 [1.1 – 1.5], <i>p</i> = 0.0178). Patients who developed progressive lung disease during follow-up showed a higher [<sup>68</sup>Ga]Pentixafor uptake compared to non-progressive patients reaching statistical significance in the left ventricle (TBR of progressive vs non-progressive patients: 2.5 (2.1 – 3.3) vs 1.5 (1.3 – 2.1), <i>p</i> = 0.0283) and showing a numerical increase in fibrotic lung regions (2.8 (2.2 – 3.3) vs 1.7 (1.1 – 2.8), <i>p</i> = 0.1535).</p> Conclusion <p>These findings provide proof-of-concept evidence that CXCR4-targeted PET/CT may visualize biologically active inflammatory and/or remodeling processes in early-stage SSc-ILD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CXCR4-targeted PET/CT in early systemic sclerosis–associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月16日

查看全文
  • Michael Gernert,
  • Marc Schmalzing,
  • Hannah Labinsky,
  • Yingjun Zhi,
  • Patrick-Pascal Strunz,
  • Matthias Fröhlich,
  • Philipp E. Hartrampf,
  • Andreas K. Buck,
  • Rudolf A. Werner,
  • Sebastian E. Serfling

摘要

Introduction

Distinguishing active inflammatory or remodeling-associated processes from irreversible fibrosis in systemic sclerosis remains challenging using conventional imaging modalities. The tracer [68Ga]Pentixafor targets the C-X-C motif chemokine receptor 4 (CXCR4) which is expressed on leukocytes. Uptake of [68Ga]Pentixafor may provide complementary biological information on CXCR4-associated inflammatory and remodeling activity.

Methods

This prospective cohort study included patients with early SSc (disease duration ≤ 5 years) and preexisting interstitial lung disease. All patients underwent [68Ga]Pentixafor-PET/CT imaging. Normalized [68Ga]Pentixafor uptake was quantified using the target-to-background ratio (TBR). Follow-up data on disease progression was collected. A control group comprised patients with giant cell arteritis.

Results

Twelve patients with SSc were included. The highest [68Ga]Pentixafor uptake was observed in the hilar and mediastinal lymph nodes, in fibrotic lung regions, and in the left ventricular myocardium. In all three regions, a significantly higher [68Ga]Pentixafor uptake was measured in SSc compared to controls (median TBR of lymph nodes 3.5 [IQR 2.7 – 4.3] vs 1.6 [1.3 – 2.0] p < 0.0001; inferior lung lobes 2.3 [1.6 – 2.8] vs 0.8 [0.7 – 1.0], p < 0.0001; and left ventricle 2.0 [1.4 – 2.4] vs 1.3 [1.1 – 1.5], p = 0.0178). Patients who developed progressive lung disease during follow-up showed a higher [68Ga]Pentixafor uptake compared to non-progressive patients reaching statistical significance in the left ventricle (TBR of progressive vs non-progressive patients: 2.5 (2.1 – 3.3) vs 1.5 (1.3 – 2.1), p = 0.0283) and showing a numerical increase in fibrotic lung regions (2.8 (2.2 – 3.3) vs 1.7 (1.1 – 2.8), p = 0.1535).

Conclusion

These findings provide proof-of-concept evidence that CXCR4-targeted PET/CT may visualize biologically active inflammatory and/or remodeling processes in early-stage SSc-ILD.